MedWatch

A part of Watch Media

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

By Albert Rønning-Andersson, translated by Daniel Pedersen

The year 2020 was written into history as a true annus horribilis for hearing aid manufacturers, whose primary customer segment comprises of the oldest part of the population, who largely kept away from audiologist appointments because of the Covid-19 pandemic.

2021 has turned out differently – at least on the private hearing aid market in the US, which is the world’s biggest single market, where sales of hearing aids went up by 37 percent compared to the year before, which was calculated from a total of 4.73 million units sold in 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Foto: Thomas Borberg/Politiken/Ritzau Scanpix

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

  1. Top news from MedWatch this week
  2. Extra data boosts Lundbeck's agitation case
  3. Acquisitions to help Coloplast attain growth goal
  4. Coloplast conducts catheter study to highlight single-use benefits
  5. FDA confirms rejection of Y-mabs' cancer drug
  6. Novo reaches share milestone, analyst credits Wegovy
  7. FDA approves Ferring microbiotica-based treatment
  8. Analyst spies alternative buyers in the wings as Cochlear's potential Oticon acquisition raises eyebrows
  9. Analyst proposes four solutions as GN battles with ghosts of debts past
  10. Former US head of Leo Pharma gets board seat at Kempharm
  11. Novo Nordisk to test best-selling substance in stroke indication
  12. ALK CFO to step down
  13. Potential Demant divestment raises competition concerns
  14. Pharmacosmos tight-lipped on competitor's Chinese market nod
  15. UK authority warns of Dupixent adverse effects

See all

Job

See all jobs

See all jobs